



HAL
open science

CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language

Lot Snijders Blok, Justine Rousseau, Joanna Twist, Sophie Ehresmann, Motoki Takaku, Hanka Venselaar, Lance H Rodan, Catherine B. Nowak, Jessica Douglas, Kathryn J Swoboda, et al.

► To cite this version:

Lot Snijders Blok, Justine Rousseau, Joanna Twist, Sophie Ehresmann, Motoki Takaku, et al.. CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language. *Nature Communications*, 2018, 9 (1), pp.4619. 10.1038/s41467-018-06014-6 . hal-01922858

HAL Id: hal-01922858

<https://hal.sorbonne-universite.fr/hal-01922858>

Submitted on 14 Nov 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ARTICLE

DOI: 10.1038/s41467-018-06014-6

OPEN

CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language

Lot Snijders Blok, Justine Rousseau, Joanna Twist et al.[#]

Chromatin remodeling is of crucial importance during brain development. Pathogenic alterations of several chromatin remodeling ATPases have been implicated in neurodevelopmental disorders. We describe an index case with a de novo missense mutation in *CHD3*, identified during whole genome sequencing of a cohort of children with rare speech disorders. To gain a comprehensive view of features associated with disruption of this gene, we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo *CHD3* mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs. Experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling. We implicate de novo *CHD3* mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.

Correspondence and requests for materials should be addressed to S.E.F. (email: simon.fisher@mpi.nl) or to P.M.C. (email: p.campeau@umontreal.ca). [#]A full list of authors and their affiliations appears at the end of the paper.

The Chromodomain Helicase DNA-binding (CHD) protein family is a key class of ATP-dependent chromatin remodeling proteins, which utilize energy derived from ATP hydrolysis to regulate chromatin structure, thereby modulating gene expression^{1,2}. CHD proteins are crucial for developmental processes^{1,3}, with various members implicated in major neurodevelopmental disorders including CHD2 in epileptic encephalopathy⁴, CHD7 in CHARGE syndrome⁵, CHD8 in autism^{6,7}, and more recently CHD4 and CHD1 in neurodevelopmental syndromes^{8,9}. Three CHD proteins (CHD3, CHD4, and CHD5) can exert their chromatin remodeling activity by forming the core ATPase subunit of the NuRD complex^{1,10–12}. The NuRD complex is associated with various fundamental cellular mechanisms, including genomic integrity and cell cycle progression¹³, and plays important roles in embryonic stem cell differentiation¹⁴. A recent study reports that the different CHD factors within the NuRD complex (CHD3, CHD4, and CHD5) are developmentally regulated in the mouse brain, each having distinct and mostly non-redundant functions during cortical development¹⁵. In particular, the CHD3 protein has been implicated in late neural radial migration and cortical layer specification.

In contrast to most other members of the CHD protein family, a specific syndrome associated with mutations in *CHD3* (MIM 602120) has not yet been characterized. In this study, based on an index case from whole genome sequencing of children with rare speech disorders, we assemble a set of 35 probands carrying de novo mutations that disrupt *CHD3*. We characterize the overlapping phenotypic features of probands with *CHD3* mutations, including intellectual disability (with a wide range of severity), developmental delays, macrocephaly, impaired speech and language skills, and characteristic facial features. We identify mainly missense mutations that cluster in and around the ATPase/helicase domain of the CHD3 protein, and are predicted to disturb function, based on three-dimensional modeling. We use functional assays to describe the effects of multiple different CHD3 mutations on ATPase activity and chromatin remodeling capacities. Taken together, our data demonstrate that de novo missense mutations in *CHD3* disturb chromatin remodeling activities of the encoded protein, thereby causing a neurodevelopmental disorder.

Results

De novo CHD3 mutations cause a neurodevelopmental phenotype. During whole genome sequencing of a cohort of 19 unrelated children with a primary diagnosis of Childhood Apraxia of Speech (CAS)¹⁶, we discovered a de novo missense mutation in *CHD3*, predicted to disrupt the helicase domain of the encoded protein. CAS is a rare neurodevelopmental disorder characterized by impairments in learning to produce the coordinated sequences of mouth and face movements underlying fluent speech. Remarkably, the CHD3 protein is one of the few documented interaction partners of FOXP2 (see Supplementary Table S1 in ref. 17), a transcription factor that has been implicated in monogenic forms of CAS, accompanied by wide-ranging language problems, in multiple families and unrelated cases^{18–20}.

Discovery of the *CHD3* mutation (NM_001005273.2, p. Arg1169Trp) in our index case motivated a search for other de novo mutations in this gene. Studies of large numbers of simplex families with an autistic proband have documented just two single non-synonymous de novo variants in *CHD3* in probands^{21,22}, while eight additional non-synonymous variants were recently recorded in a study of thousands of children with unexplained developmental disorders from the UK²³, with limited information on phenotypic profiles of carriers of *CHD3* variants. Via GeneMatcher²⁴ we assemble a cohort of 35 independently

diagnosed probands with de novo mutations disrupting *CHD3*, to systematically assess the phenotypic consequences of damage to this gene.

The 35 probands with de novo mutations in *CHD3* show overlapping phenotypes, summarized in Table 1 and in more detail in Supplementary Data 1. All individuals have global developmental delays and/or intellectual disability, with a total IQ varying from 70–85 (borderline intellectual functioning) to below 35 (severe intellectual disability). Nine individuals (29%) show autism or autism-like features, including stereotypic and hand-flapping behavior. Interestingly, the majority of individuals (19 individuals; 58%) have macrocephaly, and in cases where neuroimaging has been performed, widening of cerebrospinal fluid spaces is noted in 10 out of 30 MRI reports (33%). One individual (individual 5) has microcephaly. Hypotonia is reported in 21 individuals (75%). The facial phenotype consists of widely spaced eyes, a broad and bossing forehead, periorbital fullness and narrow palpebral fissures, laterally sparse eyebrows, low-set and often simple ears with thick helices, and a pointed chin (Fig. 1). Joint dislocations and/or hyperlaxity are reported in 12 cases, and five individuals have inguinal or umbilical hernias. Five of the 21 male individuals have undescended testes. Vision problems are quite common and include hypermetropia (11 individuals), strabismus (10 individuals), and cerebral visual impairment (three individuals). One individual (individual 34) developed epilepsy, two additional individuals had neonatal convulsions. In many individuals an abnormal and often

Table 1 Summary of phenotypes found in this cohort of probands with *CHD3* mutations

	Amount	Percentage
Development		
ID/DD	35/35	100%
<i>Degree of ID/DD</i>		
Borderline ID	3/35	9%
Mild or mild-moderate ID	9/35	26%
Moderate or moderate-severe ID	8/35	23%
Severe ID	7/35	20%
DD/level unknown	8/35	23%
Speech delay/disorder	33/33	100%
Autism or autism-like features	9/31	29%
Neurology		
Hypotonia	21/28	75%
Macrocephaly	19/33	58%
Widened CSF spaces (MRI)	10/30	33%
Neonatal feeding problems	10/32	31%
Dysmorphisms		
High, broad, and/or prominent forehead	28/33	85%
Widely spaced eyes	24/31	77%
Other		
Joint laxity (generalized and/or local)	12/30	40%
<i>Vision problems</i>		
Hypermetropia	11/29	38%
Strabismus	10/33	30%
Cerebral visual impairment	3/33	9%
Genital abnormalities in males	6/17	35%
Hernia (inguinal, umbilical, hiatal)	5/28	18%

More extensive clinical information per individual is provided in Supplementary Data 1. As information on the different features was not always applicable or known for each patient, the denominator in the "Amount" column is different for different clinical characteristics




Fig. 1 Photographs of affected individuals. Facial photographs showing dysmorphisms in 18 individuals with de novo *CHD3* mutations. The majority of individuals have macrocephaly with a prominent or bossing forehead, individual 5 has microcephaly. Hypertelorism or telecanthus is common, often accompanied by narrow palpebral fissures, deep-set eyes, peri-orbital fullness, and/or epicanthal folds. The combination of macrocephaly and deep-set eyes leads to a more prominent supra-orbital ridge. Some individuals show midface hypoplasia. Many individuals have low-set ears that can be posteriorly rotated, and sometimes simple with thick helices. A broad nasal base, prominent nose, a bifid nasal tip, and characteristic pointy chin is also frequently seen, as well as laterally sparse eyebrows

unsteady gait is reported, and one individual (individual 13) developed symptoms of Parkinsonism at a later age.

Given that our index case was ascertained on the basis of a formal diagnosis of CAS, we pay special attention to the association of *CHD3* mutations with speech and language deficits. The index case was diagnosed with severe speech apraxia at the age of 3 years, and then used sign language to communicate effectively. He has severe problems with expressive speech, against relatively normal scores on language comprehension tests and a composite IQ (KBIT) of 72. In all 33 subjects that were at least 2 years old at the last evaluation, *CHD3* disruptions are associated with delayed milestones in the speech and language domain. The average age for first spoken words in this cohort is 2 years and 10 months (range: 1.5–5.5 years, after excluding six individuals that were non-verbal at the last evaluation). Our data suggest that expressive language is more affected than receptive language, and intelligibility is often impaired. Speech-related problems identified in our cohort include dysarthria, speech apraxia, oromotor problems, and stuttering.

De novo *CHD3* mutations cluster in the helicase domain. The 35 unrelated probands have 23 different de novo mutations in *CHD3* (Fig. 2a, b). None of these mutations are present in the GnomAD database (<http://gnomad.broadinstitute.com>). Except for four individuals, all individuals have missense mutations. Interestingly, within our cohort there are multiple cases of recurrent identical de novo mutations, revealing mutational hotspots. The most striking is p.Arg985Trp, found in six children from five different families, while two additional individuals have a different substitution affecting the same residue (p.Arg985Gln).

The *CHD3* protein is characterized by a SNF2-like ATPase/helicase domain, together with two plant homeodomain (PHD) fingers and two chromodomains (Fig. 2b, c)^{1,11}, which mediate chromatin interactions and nucleosome remodeling¹. The overwhelming majority of missense mutations (17/19) cluster within and around the ATPase/helicase motif, a functional domain that consists of two subdomains: a Helicase ATP-binding lobe and a Helicase C-terminal lobe. This domain provides energy for nucleosome remodeling through its ATPase activity. All missense mutations affect amino acids that are highly conserved, both in different species and also in the other CHD proteins that can be part of the NuRD complex (Supplementary Fig. 1), and clearly cluster in and around highly conserved SF2-family helicase motifs (Supplementary Fig. 1). All are predicted to be pathogenic by PolyPhen-2 and/or SIFT, and have CADD scores above 24 (Supplementary Data 1).

The identified de novo mutations also include one in-frame deletion of one amino acid (p.Gly1109del) and two truncating mutations (p.Glu457* and p.Phe1935Glufs*108), although the latter causes a frameshift at the very end of the protein, leading to a stop codon after 108 amino acids. RNA sequencing of transcripts with and without cycloheximide showed that this mutation escapes nonsense-mediated decay (Supplementary Fig. 2). Finally, one case has a splice-site mutation (c.4073-2A>G) which is predicted to yield skipping of exon 27, while preserving the reading frame (Fig. 2a). Data from the ExAC database (<http://exac.broadinstitute.com>) indicate that *CHD3* is extremely intolerant for loss-of-function mutations (loss-of-function intolerance score of 1.0) and highly intolerant for missense mutations (*Z*-score of +7.15)²⁵, supporting the pathogenicity of the mutations that we found.

All *CHD3* mutations were determined to be the most likely causal variant contributing to the disorder of the proband. In proband 15 who has a de novo *CHD3* p.Asp1120His mutation, a de novo truncating mutation in *CIC* was also identified

(NM_015125.3:c.1444G>T; p.Glu482*). Since truncating mutations in *CIC* were recently suggested as a potential cause of intellectual disability (ID)²⁶, both mutations might be involved in the phenotype of this proband.

A subset of *CHD3* mutations directly affects ATP hydrolysis.

The striking clustering of almost all missense mutations in the ATPase/helicase domain of the *CHD3* protein led us to hypothesize that disturbance of ATPase and/or chromatin remodeling activities of *CHD3* could be potential pathogenic mechanisms. Three-dimensional modeling and mutation analysis of all missense mutations, including analysis of the conserved SF2-characteristic helicase motifs, demonstrates clear clustering of mutations and disturbance of important binding and interaction domains (Fig. 2d and Supplementary Note 1). Direct fluorescence imaging of mCherry-tagged *CHD3* mutations in cellular models revealed no differences in subcellular localization for the mutated proteins as compared to wild-type *CHD3* (Supplementary Fig. 3).

We experimentally assessed ATPase activity of six representative mutations, selected to include one mutation in the Helicase ATP-binding lobe and several mutations in the Helicase C-terminal lobe. FLAG-tagged full-length wild-type *CHD3* protein and each of the six mutant proteins were transiently expressed in mammalian HEK293 cells and purified (Supplementary Fig. 4). Radiometric ATPase assays were performed to assess the activity of these mutant proteins relative to wild-type, in the presence of dsDNA (Fig. 3), recombinant nucleosomes (Fig. 3), or in the absence of DNA substrates as a control (Supplementary Fig. 5). ATPase activities of p.Arg1121Pro and p.Arg1172Gln were significantly lower than wild-type for both substrate conditions. These findings are consistent with the modeling data, since p.Arg1121Pro is predicted to disrupt a helix integral to motif V, while p.Arg1172Gln is located in helicase motif VI, and both motifs are known to be critical in ATP hydrolysis. The activity of p.Asn1159Lys was significantly lower only in the presence of dsDNA, although the reason for the different activity depending on the substrate is currently unknown. The protein with the p.Leu915Phe mutation, located in conserved SNF2-motif III, is significantly hyperactive under both conditions. The p.Arg1187Pro and p.Trp1158Arg mutations do not show statistically significant differences from the wild-type protein in these ATPase assays. According to the three-dimensional structure, the location of p.Arg1187Pro is not close to the ATP-binding or interaction surface. To assess whether mutant protein could impact activity of wild-type enzyme, we mixed wild-type protein with equimolar amounts of several mutant proteins, finding no biochemical evidence in this assay for interference (Supplementary Fig. 6).

***CHD3* mutations disturb chromatin remodeling capacities.**

We measured the effects of six mutations on the chromatin remodeling activity of *CHD3*, by assessing restriction enzyme accessibility to nucleosomal DNA²⁷. Consistent with its reduced activity in the ATPase assays, the p.Arg1172Gln mutant was partially, but not fully, active at chromatin remodeling (Fig. 4). p.Arg1121Pro, which showed severely reduced ATPase activity, was highly compromised in the chromatin remodeling assay. Moreover, p.Leu915Phe demonstrated hyperactivity in this assay, mirroring its elevated ATPase activity. Crucially, chromatin remodeling assays can also detect functional defects beyond ATP hydrolysis²⁷. Two of the mutant proteins, p.Trp1158Arg and p.Asn1159Lys, exhibited severely compromised ability to remodel chromatin (Fig. 4) against a background of some preserved ATPase activity (c.f. Fig. 3). In sum, with the sole exception of p.Arg1187Pro, all the mutant versions of *CHD3* that we tested differ from wild-type protein in their ability to remodel




Fig. 2 Schematic view of CHD3 transcript and protein with de novo mutations. **a** Schematic view of CHD3 exons (transcript 1, NM_001005273.2) with the splice site mutation c.4073-2A>G shown that most likely leads to skipping of exon 27 (22 amino acids), while preserving the reading frame. Exon 27 is part of the beginning of the second DUF domain (DUF 1086). Colors of the domains in **a** match with colors of domains in **b** and **c**. Five different types of domains are specified: plant homeodomains (PHD), chromodomains (Chromo), a Helicase domain consisting of two parts (Helicase ATP-binding and Helicase C-terminal), domains of unknown function (DUF), and a C-terminal 2 domain. **b** Schematic view of linear CHD3 protein (transcript 1, NM_001005273.2) with all mutations, except for the splice site mutation that is shown in **a**, found in our cohort. Almost all missense mutations cluster in or around the Helicase domain of the CHD3 protein. **c** Overview of one of the two CHD3-models used in this study, based on the 3MWY protein structure. This figure shows the different domains of the protein in their three-dimensional conformation: chromo domain 1 494–595 (magenta), chromo domain 2 631–673 (red), helicase ATP binding domain (yellow), helicase C-terminal domain (green), ATP binding residues 761–768 (cyan). ATP is orange, and gray residues do not belong to an indicated domain. Colors of the domains in **c** match with colors of domains in **a** and **b**. **d** The same structure as **c**, but in this figure the positions of the mutated residues are indicated in red, the sidechains of these residues are shown as red balls. The ATP molecule is shown in yellow. This figure illustrates the clustering of mutations on specific sites within the Helicase ATP-binding domain and Helicase C-terminal domain. A more detailed analysis of the different missense mutations in our cohort can be found in Supplementary Note 1




Fig. 3 ATPase assays. Radiometric ATPase assays were performed to assess the activity of the mutant proteins relative to wild-type, in the presence of recombinant nucleosomes (blue), dsDNA (green), or in the absence of DNA substrates as a control (Supplementary Fig. 4). Released phosphate was separated from unhydrolyzed ATP by thin layer chromatography, and detected by exposure to a phosphorimager. The experimental values (percentage hydrolyzed ATP) for the different mutant conditions were normalized to values for the wild-type condition within the experiment, to derive a normalized ATPase activity. The experimental data are presented as means \pm standard deviation, individual data points are shown as red triangles. Three independent experiments from two individual purifications (wild-type, p.Leu915Phe, p.Arg1121Pro, p.Asu1159Lys, p.Arg1172Gln, and p.Arg1187Pro) ($N = 6$) or one purification (p.Trp1158Arg) ($N = 3$) were performed. Raw values from the individual experiments can be found in Supplementary Data 2. Asterisk (*) indicates significant difference for mutant values compared to wild-type values (unpaired t -test, $P < 0.05$) within the same substrate condition

chromatin, with some mutants exhibiting decreased activity while one shows increased activity.

Discussion

In this study, we show that de novo *CHD3* mutations cause a neurodevelopmental disorder. We demonstrate defining clinical features of this syndrome. The characteristic phenotype of individuals with *CHD3* mutations overlaps with that reported for de novo mutations in *CHD4*, in which intellectual disability, macrocephaly, ventriculomegaly, undescended testes, and similar facial features have been reported. However, comparisons to the *CHD4*-related syndrome are currently limited because so far only five individuals with *CHD4* mutations have been clinically characterized. Also interesting in this context is the fact that four of the six recently described patients with missense mutations in *CHD1* have a diagnosis of speech apraxia⁹, a relatively rare condition. Although *CHD1* does not function in the same protein complex as *CHD3* and has different expression patterns⁹, there might be shared pathogenic mechanisms leading to speech problems in patients with mutations in these chromatin remodelers.

Based on the molecular and phenotypic data of individuals in our cohort, there is no obvious correlation between the precise type or location of the mutation, and the severity of the variable features of the resulting syndrome. However, the only individual in our cohort with epilepsy is also the only case with a missense mutation in the C-terminal domain of the protein. Future identification of more individuals with missense mutations in this region of the protein will help resolve whether this reflects a phenotype-genotype correlation.

In addition to defining the phenotype associated with *CHD3* mutations, we aimed to characterize the effects of *CHD3* mutations at a molecular and functional level. ATPase assays with six different mutant *CHD3* constructs showed a clearly decreased ATPase activity for two mutations (p.Arg1121Pro and p.Arg1172Gln) and increased ATPase activity for one mutation (p.Leu915Phe). The disturbed ATPase activities are associated with corresponding effects on chromatin remodeling capacities for these three mutants,

as shown by the restriction enzyme accessibility assays. It is currently unclear how deactivating and activating mutations can both yield similarly disruptive effects on neurodevelopmental outcomes. However, a recent study of cancer-specific mutations in the chromatin remodeling ATPase SMARCA4 concluded that mutations in the ATPase core of this enzyme had dominant-negative impacts on the global chromatin landscape regardless of whether they displayed increased or decreased dynamic recovery in fluorescence after photobleaching²⁸. By analogy, it seems plausible that perturbed chromatin remodeling activity of *CHD3*, whether by gain or loss of activity relative to wild-type or by affecting its interactions, might likewise alter chromatin landscapes, to contribute to a neurodevelopmental phenotype.

Two mutations (p.Trp1158Arg and p.Asu1159Lys) show severely decreased chromatin remodeling capacities, despite unaffected ATPase activity in the presence of recombinant nucleosomes. In line with these findings, the highly conserved tryptophan residue at a position analogous to *CHD3* residue 1158 has recently been shown to be critical for chromatin remodeling, but not for ATP hydrolysis, in the context of yeast SNF2²⁷. Interestingly, the mutation in our cohort affecting this amino acid (p.Trp1158Arg) directly matches the position of a previously published mutation in *CHD4*⁸ (Supplementary Fig. 1), while the other previously published de novo missense mutations in *CHD4*-related syndrome are also mainly affecting the orthologous Helicase domain of *CHD4* (Supplementary Fig. 1)^{8,29}.

To systematically assess whether the distribution of the missense mutations in *CHD3* reflects mutational hotspots in the gene, we performed a formal clustering analysis based on mutual distances, as previously described³⁰. This analysis revealed significant clustering within the transcript ($P = 0.0017$), a finding that argues against simple haploinsufficiency as an underlying molecular mechanism. The paucity of patients with truncating mutations compared to the 31 patients with missense mutations in our cohort also supports this view, although the precise mechanistic effects of *CHD3* mutations during neurodevelopment are a topic for future study.




Fig. 4 Restriction enzyme accessibility assay. **a** Restriction enzyme accessibility analysis of CHD3 wild-type and mutant proteins. 3.125, 6.25, or 12.5 nM of CHD3 proteins were incubated with 347 bp mono-nucleosomes. Digested fragments were analyzed by native polyacrylamide gel. **b** Quantitative analysis of restriction enzyme accessibility. Three individual experiments from two individual purifications (wild-type, p.Leu915Phe, p.Arg1121Pro, p.Asn1159Lys, p.Arg1172Gln, and p.Arg1187Pro) ($N = 6$) or one purification (p.Trp1158Arg) ($N = 3$) were conducted. The experimental data are presented as means with standard deviations

Taken together, with our research we identify a recognizable neurodevelopmental disorder. We define the phenotypic spectrum associated with mutations in *CHD3*, and show the effects of several different mutations on ATPase activity and chromatin remodeling capacities. Our findings highlight the importance of chromatin remodeling factors, and specifically the CHD3 protein, in human brain development.

Methods

Individuals and consents. The authors affirm that (the legal representatives of) all human research participants provided informed consent for publication of the images in Fig. 1. Informed consent was also derived for the use of biological materials from all individuals or their legal representative. Genetic testing and research were performed in accordance with protocols approved by the local Institutional Review Boards where the patients were followed. Specifically, research exomes were performed after informed consent on protocols approved by the Institutional Review Boards of the following institutions: University of British Columbia, Augustana College, CHU Dijon, Mass General Hospital for Children, University of Erlangen-Nuremberg, Hamburg Chamber of Physicians, Cambridge South—UK Research Ethics Committee, University of Wisconsin-Madison Social & Behavioral Sciences.

Annotation of mutations. All mutations in this report are annotated in GRCh37 (hg19) and CHD3 transcript variant 1 (NM_001005273.2).

Next-generation sequencing. For the index case (individual 22), whole genome sequencing was performed using Illumina's HiSeq X Ten technology, the Burrows–Wheeler Aligner (BWA) software version 0.7.8-r455³¹ and GATK v.3.4³². In other individuals, exome or genome sequencing and data analysis were performed as previously described^{33–44}.

Expression and purification of FLAG-CHD3. CHD3 proteins were prepared as previously described⁴⁵, with the following modifications. FLAG-CHD3 constructs were cloned into expression vectors (kindly provided by Guang Hu) using Gateway Cloning technology. Primer sequences are provided in Supplementary Table 1. HEK293-f (ThermoFisher, FreeStyle™ 293-F Cells) were grown in suspension culture using FreeStyle™ 293 Expression Medium (ThermoFisher) in optimum growth flasks (Thomson) using a shaking incubator set at 8% CO₂, 80% humidity, and 150 rpm shaker rate. The cell count was 10⁶ cells/ml on the day of transfection. Cells were transfected with 1 mg of expression vector using PEI max (Polysciences). Cells were harvested 48 h after transfection by centrifugation at 400 × g for 6 min. Cells were washed once with phosphate buffer saline solution prior to storage at –80 °C or protein purification.

The cell pellet was resuspended in lysis buffer (20 mM HEPES, 1.5 mM MgCl₂, 10 mM KCl, 1 mM DTT, 1 mM PMSF, and 1× cOmplete® protease-inhibitor EDTA-free (Roche), pH 7.6). Cells were incubated on ice for 30 min, vortexed briefly, and nuclei were collected by centrifugation (5 min, 3300 × g, 4 °C). The supernatant was discarded and the nuclear pellet was resuspended in nuclear extraction buffer (20 mM HEPES, 0.5 M KCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 20% glycerol, 0.2% NP-40, 1 mM DTT, 1 mM PMSF, and 1× cOmplete® protease-inhibitor EDTA-free (Roche), pH 7.6). The nuclear pellet was homogenized using a Dounce homogenizer, incubated on ice for 30 min, and insoluble material was removed by centrifugation (20 min, 110,000 × g, 4 °C). The supernatant (nuclear extract) was incubated with α-FLAG M2 affinity gel (Sigma-Aldrich) and rotated overnight at 4 °C. The α-FLAG beads were then washed twice with nuclear extraction buffer, followed by 2 additional washes with wash buffer (20 mM HEPES, 0.1 M KCl, 0.2% NP-40, 20% glycerol, and 1 mM DTT, pH 7.6). The FLAG-CHD3 protein was eluted with 0.3 mg/ml 3XFLAG peptide (in 20 mM HEPES, 0.1 M KCl, 0.05% NP-40, 20% glycerol, and 1 mM DTT, pH 7.6). Wild-type and mutant protein samples were analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue (Supplementary Fig. 4). The concentration of the CHD3 proteins was estimated from BSA standards in SDS-PAGE gels stained with Coomassie Brilliant Blue.

Radiometric ATPase assay. Each ATPase reaction (10 μL) contained 20 mM Tris–HCl, pH 7.5, 1 mM MgCl₂, 0.1 mg/ml BSA, 1 mM DTT, 100 μM ATP, 1 μCi of [^γ-³²P]ATP as a tracer. 25 nM of each CHD3 purified protein was incubated with 70 nM of recombinant nucleosomes or naked dsDNA. Nucleosome was reconstituted by the salt gradient dialysis method using recombinant histone octamer and 201 bp 601 DNA fragment⁴⁶. The reactions were initiated by the addition of nucleosome or DNA substrate and incubated at 37 °C for 40 min. The reaction was quenched by the addition of EDTA to a final concentration of 100 mM. Aliquots (2.5 μL) were removed and spotted on PEI-cellulose thin-layer chromatography plates and developed in 1 M formic acid and 0.5 M LiCl. ATP hydrolysis was quantified using a Phosphorimager with Image Quant Software. For the mixing experiment, all reaction components except for CHD3 protein were incubated for 10 min at 37 °C, and the CHD3 protein mixture was added last to start the reaction. This experiment was performed 3 times per condition ($N = 3$) for all conditions, except for the conditions “no CHD3”, “WT 12.5 nM” and “WT 25 nM” ($N = 2$).

For the quantification analysis, we performed 3 individual experiments for each of the two biological replicates (total $N = 6$), except for the p.Trp1158Arg mutant (one biological replicate, total $N = 3$). An unpaired *t*-test was used to determine whether the activity of the mutant proteins differed significantly from wild-type protein activity.

Restriction enzyme accessibility assay. Remodeling activities were measured with a restriction enzyme accessibility assay as previously described²⁷. 12.5 nM nucleosomes (347 bp) were incubated with the indicated amounts of CHD3 proteins at 37 °C for 60 min in the remodeling buffer (20 mM Tris–HCl pH 7.5, 1 mM DTT, 1 mM MgCl₂, 1 mM ATP, 0.1 mg/ml BSA, and 5 U HhaI). The reactions were stopped by adding 2 μL of proteinase K buffer containing 6.7 mg/ml proteinase K, 167 mM EDTA, and 1.7% SDS. After incubation at 50 °C for 10 min, the DNAs were analyzed by 6% native polyacrylamide gel electrophoresis. The separated DNA fragments were visualized with UV light on the ChemiDox XRS system (BIO-RAD). The band intensities were quantified by ImageJ.

Cloning constructs for immunofluorescence. Wild-type CHD3 (NM_001005273.2) was amplified by PCR and cloned into pCR2.1-TOPO (Invitrogen) as described⁴⁷. CHD3 mutation constructs were generated using the QuikChange II Site-Directed Mutagenesis Kit (Agilent), primer sequences are provided in Supplementary Table 1. CHD3 cDNAs were subcloned using BamHI/NheI restriction sites into a modified pmCherry-C1 vector (Clontech). All constructs were verified by Sanger sequencing.

Immunofluorescence. HEK293 cells were obtained from ECACC (Catalogue number 85120602) and grown in Dulbecco's modified Eagle's medium (Invitrogen), supplemented with 10% fetal bovine serum (Invitrogen). Transfection was performed using GeneJuice (Merck-Millipore). The cells were seeded onto coverslips coated with poly-L-lysine (Sigma). At 36 h post-transfection, cells were fixed using 4% paraformaldehyde solution (Electron Microscopy Sciences) for 10 min at room temperature. The mCherry fusion proteins were visualized by direct fluorescence, nuclei were visualized with Hoechst 33342 (Invitrogen). Fluorescence images were obtained using an Axiovert A-1 fluorescent microscope with ZEN Image Software (Zeiss).

Three-dimensional modeling. As no experimentally solved 3D-structure of CHD3 exists, we performed homology modeling using the modeling option with standard parameters in the YASARA⁴⁸ & WHAT IF⁴⁹ twinset. Several models of the ATPase/helicase domain were created. The best scoring model was based on template PDB-file 5JXR (sequence identity 41% over the aligned residues). We also studied the model based on PDB-file 3MWY (sequence identity 45%), which shows a more open conformation and contains an ATP substitute. These two models provided information about the relative position of the mutated residues in the different conformation of the protein complex.

Clustering analysis of missense mutations. The locations of observed de novo missense mutations were permuted 1,000,000 times over the cDNA of the CHD3 gene (RefSeq transcript: NM_001005273.2). The distances between missense mutations were adjusted to take into account the total size of the coding region of CHD3 (6003 bp). Then, the geometric mean (the n th root of the product of n of all distances separating the mutations) was calculated, giving an index of clustering, as previously described³⁰. To circumvent a mean distance of 0 as the result of recurrent mutations, pseudocount (adding 1 to all distances and 1 to the gene size) was used. To avoid artificial deflation of the clustering P -value, only one of the recurrent mutations present in the sibling-pair (individuals 7 and 8) and twin-pair (individuals 20 and 21) were included for the analysis.

Data availability

All genotypic and phenotypic data supporting the findings of this study are available within the paper and supplementary files. Data are also freely available in the ClinVar database, under accession numbers SCV000787629–SCV000787651. Raw data of functional experiments are available from the corresponding authors (P.M.C. and S.E.F.) upon request.

Received: 9 November 2017 Accepted: 27 July 2018

Published online: 05 November 2018

References

- Marfella, C. G. & Imbalzano, A. N. The Chd family of chromatin remodelers. *Mutat. Res.* **618**, 30–40 (2007).
- Hargreaves, D. C. & Crabtree, G. R. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. *Cell Res.* **21**, 396–420 (2011).
- Ho, L. & Crabtree, G. R. Chromatin remodelling during development. *Nature* **463**, 474–484 (2010).
- Carvill, G. L. et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nat. Genet.* **45**, 825–830 (2013).
- Vissers, L. E. et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. *Nat. Genet.* **36**, 955–957 (2004).
- O'Roak, B. J. et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* **485**, 246–250 (2012).
- Bernier, R. et al. Disruptive CHD8 mutations define a subtype of autism early in development. *Cell* **158**, 263–276 (2014).
- Weiss, K. et al. De novo mutations in CHD4, an ATP-dependent chromatin remodeler gene, cause an intellectual disability syndrome with distinctive dysmorphisms. *Am. J. Hum. Genet.* **99**, 934–941 (2016).
- Pilarowski, G. O. et al. Missense variants in the chromatin remodeler CHD1 are associated with neurodevelopmental disability. *J. Med. Genet.* **55**, 561–566 (2017).
- Zhang, Y., LeRoy, G., Seelig, H. P., Lane, W. S. & Reinberg, D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. *Cell* **95**, 279–289 (1998).
- Woodage, T., Basrai, M. A., Baxevanis, A. D., Hieter, P. & Collins, F. S. Characterization of the CHD family of proteins. *Proc. Natl Acad. Sci. USA* **94**, 11472–11477 (1997).
- Kolla, V. et al. The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex. *Biochem. J.* **468**, 345–352 (2015).
- Lai, A. Y. & Wade, P. A. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. *Nat. Rev. Cancer* **11**, 588–596 (2011).
- Basta, J. & Rauchman, M. The nucleosome remodeling and deacetylase complex in development and disease. *Transl. Res.* **165**, 36–47 (2015).
- Nitaraska, J. et al. A functional switch of NuRD chromatin remodeling complex subunits regulates mouse cortical development. *Cell Rep.* **17**, 1683–1698 (2016).
- Eising, E. et al. A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development. *Mol. Psychiatry*. <https://doi.org/10.1038/s41380-018-0020-x> (2018).
- Estruch, S. B., Graham, S. A., Deriziotis, P. & Fisher, S. E. The language-related transcription factor FOXP2 is post-translationally modified with small ubiquitin-like modifiers. *Sci. Rep.* **6**, 20911 (2016).
- Lai, C. S., Fisher, S. E., Hurst, J. A., Vargha-Khadem, F. & Monaco, A. P. A forkhead-domain gene is mutated in a severe speech and language disorder. *Nature* **413**, 519–523 (2001).
- Graham, S. A. & Fisher, S. E. Understanding language from a genomic perspective. *Annu. Rev. Genet.* **49**, 131–160 (2015).
- Morgan, A., Fisher, S.E., Scheffer, I. & Hildebrand, M. FOXP2-related Speech and Language Disorders. in *GeneReviews(R)* (eds Pagon, R.A. et al.) (Seattle, WA, 2017).
- Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature* **515**, 216–221 (2014).
- Yuen, R. K. et al. Genome-wide characteristics of de novo mutations in autism. *Genom. Med.* **1**, 16027 (2016).
- Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* **542**, 433–438 (2017).
- Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum. Mutat.* **36**, 928–930 (2015).
- Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).
- Lu, H. C. et al. Disruption of the ATXN1-CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans. *Nat. Genet.* **49**, 527–536 (2017).
- Liu, X., Li, M., Xia, X., Li, X. & Chen, Z. Mechanism of chromatin remodelling revealed by the Snf2-nucleosome structure. *Nature* **544**, 440–445 (2017).
- Hodges, H. C. et al. Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. *Nat. Struct. Mol. Biol.* **25**, 61–72 (2018).
- Sifrim, A. et al. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. *Nat. Genet.* **48**, 1060–1065 (2016).
- Lelieveld, S. H. et al. Spatial clustering of de novo missense mutations identifies candidate neurodevelopmental disorder-associated genes. *Am. J. Hum. Genet.* **101**, 478–484 (2017).
- Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
- DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat. Genet.* **43**, 491–498 (2011).
- Neveling, K. et al. A post-hoc comparison of the utility of Sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. *Hum. Mutat.* **34**, 1721–1726 (2013).
- Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. *Nature* **519**, 223–228 (2015).
- Hollink, I. et al. Acute myeloid leukaemia in a case with Tatton–Brown–Rahman syndrome: the peculiar DNMT3A R882 mutation. *J. Med. Genet.* **54**, 805–808 (2017).
- Gibson, W. T. et al. Mutations in EZH2 cause Weaver syndrome. *Am. J. Hum. Genet.* **90**, 110–118 (2012).
- Cohen, A. S. et al. A novel mutation in EED associated with overgrowth. *J. Hum. Genet.* **60**, 339–342 (2015).
- Lelieveld, S. H. et al. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat. Neurosci.* **19**, 1194–1196 (2016).
- Thevenon, J. et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. *Clin. Genet.* **89**, 700–707 (2016).
- Louie, R. J. et al. Novel pathogenic variants in FOXP3 in fetuses with echogenic bowel and skin desquamation identified by ultrasound. *Am. J. Med. Genet. A* **173**, 1219–1225 (2017).
- Hempel, M. et al. De novo mutations in CHAMP1 cause intellectual disability with severe speech impairment. *Am. J. Hum. Genet.* **97**, 493–500 (2015).
- Popp, B. et al. Do the exome: a case of Williams–Beuren syndrome with severe epilepsy due to a truncating de novo variant in GABRA1. *Eur. J. Med. Genet.* **59**, 549–553 (2016).

43. Tanaka, A. J. et al. Mutations in SPATA5 are associated with microcephaly, intellectual disability, seizures, and hearing loss. *Am. J. Hum. Genet.* **97**, 457–464 (2015).
44. Kremer, L. S. et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. *Nat. Commun.* **8**, 15824 (2017).
45. Low, J. K. et al. CHD4 is a peripheral component of the nucleosome remodeling and deacetylase complex. *J. Biol. Chem.* **291**, 15853–15866 (2016).
46. Taguchi, H., Horikoshi, N., Arimura, Y. & Kurumizaka, H. A method for evaluating nucleosome stability with a protein-binding fluorescent dye. *Methods* **70**, 119–126 (2014).
47. Deriziotis, P. et al. De novo TBR1 mutations in sporadic autism disrupt protein functions. *Nat. Commun.* **5**, 4954 (2014).
48. Krieger, E., Koraimann, G. & Vriend, G. Increasing the precision of comparative models with YASARA NOVA—a self-parameterizing force field. *Proteins* **47**, 393–402 (2002).
49. Vriend, G. WHAT IF: a molecular modeling and drug design program. *J. Mol. Graph.* **8**, 29 (1990).

Acknowledgements

We thank all individuals and families for their contribution. We thank Amaia Carrión Castillo and Else Eising for assistance with the WGS analysis of the index individual, and Sarah Graham and Elliot Sollis for cloning the wild-type CHD3 construct for immunofluorescence. This work was supported by the Netherlands Organization for Scientific Research (NWO) Gravitation Grant 24.001.006 to the Language in Interaction Consortium (L.S.B., S.E.F., and H.G.B.), the Max Planck Society (S.E.F.), the National Institute on Deafness and Other Communication Disorders Grant DC000496 (L.Sh.) and a core grant to the Waisman Center from the National Institute of Child Health and Human Development (Grant U54 HD090256) to L.Sh., the Canadian Institutes of Health Research Grants MOP-119595 and PJT-148830 to W.T.G. Individuals 11, 16, 24, and 28 were part of The DDD Study cohort. The DDD Study presents independent research commissioned by the Health Innovation Challenge Fund [Grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute [Grant number WT098051]. The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health. The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12, granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network.

Author contributions

L.S.B., S.E.F., P.A.W. and P.M.C. designed the study. J.Ro., J.T., S.E., M.T., J.D.R., R.M.P., P.A.W. and P.M.C. were involved in the design and execution of the ATPase assays.

L.S.B. performed the immunofluorescence work with supervision of P.D. The three-dimensional modeling was performed by H.V. and R.P. performed the RNA analysis of the frameshift mutation. L.S.B., L.H.R., C.B.N., J.D., K.J.S., M.A.S., I.S., C.T.R.M.S., A.P.A.S., P.W., M.W., E.F., A.K., W.T.G., A.S.A.C., R.A., A.M.I., P.Y.B.A., J.Ra., I.J.A., S.A.S., R.J.L., H.E.W., A.A., B.K., C.N., J.B., A.I., D.R., R.L., J.P., T.E., M.C., S.L., J.H.C., S.P., R.E.S., G.D., I.M.W., C.Z., A.R., M.G.B., C.M., M.K., E.H.B., G.R.M., K.L.I.G., E.B., R.N.E., L.B., I.B., H.M., S.B.W., K.J.J., E.A.S., K.K., T.B., S.M., H.K., S.L., R.P., S.J., L.F., J.T., M.A., L.S., T.K., H.B. and P.M.C. participated in recruitment of individuals, phenotyping and/or next-generation sequencing analysis. L.S.B., J.Ro., J.T., S.E., M.T., J.D.R., R.M.P., T.K., H.G.B., P.A.W., S.E.F. and P.M.C. analyzed and interpreted the results and wrote the manuscript. T.K., H.G.B., P.A.W., P.M.C. and S.E.F. supervised the project. All authors contributed to the final version of the manuscript.

Additional information

Supplementary Information accompanies this paper at <https://doi.org/10.1038/s41467-018-06014-6>.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

Lot Snijders Blok^{1,2,3}, Justine Rousseau⁴, Joanna Twist⁵, Sophie Ehresmann⁴, Motoki Takaku⁵, Hanka Venselaar⁶, Lance H. Rodan⁷, Catherine B. Nowak⁷, Jessica Douglas⁷, Kathryn J. Swoboda⁸, Marcie A. Steeves⁹, Inderneel Sahai⁹, Connie T.R.M. Stumpel¹⁰, Alexander P.A. Stegmann¹⁰, Patricia Wheeler¹¹, Marcia Willing¹², Elise Fiala¹², Aaina Kochhar¹³, William T. Gibson^{14,15}, Ana S.A. Cohen^{14,15}, Ruky Agbahovbe^{14,15}, A. Micheil Innes¹⁶, P.Y. Billie Au¹⁶, Julia Rankin¹⁷, Ilse J. Anderson¹⁸, Steven A. Skinner¹⁹, Raymond J. Louie¹⁹, Hannah E. Warren¹⁹, Alexandra Afenjar²⁰, Boris Keren^{21,22}, Caroline Nava^{21,22,23}, Julien Buratti²¹, Arnaud Isapof²⁴, Diana Rodriguez²⁵, Raymond Lewandowski²⁶, Jennifer Propst²⁶, Ton van Essen²⁷, Murim Choi²⁸, Sangmoon Lee²⁸, Jong H. Chae²⁹, Susan Price³⁰, Rhonda E. Schnur³¹, Ganka Douglas³¹, Ingrid M. Wentzensen³¹, Christiane Zweier³², André Reis³², Martin G. Bialer³³, Christine Moore³³, Marije Koopmans³⁴, Eva H. Brilstra³⁴, Glen R. Monroe³⁴, Koen L.I. van Gassen³⁴, Ellen van Binsbergen³⁴, Ruth Newbury-Ecob³⁵, Lucy Bownass³⁵, Ingrid Bader³⁶, Johannes A. Mayr³⁷, Saskia B. Wortmann^{37,38,39}, Kathy J. Jakielski⁴⁰, Edythe A. Strand⁴¹, Katja Kloth⁴², Tatjana Bierhals⁴², The DDD study, John D. Roberts⁵, Robert M. Petrovich⁵, Shinichi Machida⁴³, Hitoshi Kurumizaka⁴³, Stefan Lelieveld¹, Rolph Pfundt¹, Sandra Jansen^{1,3}, Pelagia Deriziotis²

Laurence Faive^{44,45}, Julien Thevenon^{44,45}, Mirna Assoum^{44,45}, Lawrence Shriberg⁴⁶, Tjitske Kleefstra^{1,3}, Han G. Brunner^{1,3,10}, Paul A. Wade⁵, Simon E. Fisher^{2,3} & Philippe M. Campeau^{4,47}

¹Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500HB, The Netherlands. ²Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen 6500AH, The Netherlands. ³Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen 6500HE, The Netherlands. ⁴CHU Sainte-Justine Research Center, Montreal QC H3T 1C5, Canada. ⁵National Institute of Environmental Health Sciences, Research Triangle Park NC 27709, USA. ⁶Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen 6500HB, The Netherlands. ⁷Division of Genetics and Genomics, Boston Children's Hospital, Boston MA 02115, USA. ⁸Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston MA 02114, USA. ⁹Department of Medical Genetics, Massachusetts General Hospital, Boston MA 02114, USA. ¹⁰Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht 6202AZ, The Netherlands. ¹¹Nemours Childrens Clinic, Orlando FL 32827, USA. ¹²Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis MO 63110, USA. ¹³Valley Children's Hospital, Madera CA 93636, USA. ¹⁴British Columbia Children's Hospital Research Institute, Vancouver BC V5Z 4H4, Canada. ¹⁵Department of Medical Genetics, University of British Columbia, Vancouver BC V6H 3N1, Canada. ¹⁶Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary AB T2N 4N1, Canada. ¹⁷Department of Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust (Heavitree), Exeter EX2 5DW, UK. ¹⁸Division of Genetics, Department of Medicine, University of Tennessee Medical Center, Knoxville TN 37920, USA. ¹⁹Greenwood Genetic Center, Greenwood SC 29646, USA. ²⁰GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris ; Department of Medical Genetics and Centre de Référence Malformations et maladies congénitales du cervelet et déficiences intellectuelles de causes rares, Armand Trousseau Hospital, GHUEP, AP-HP, Paris 75012, France. ²¹AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris 75013, France. ²²Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris 75005, France. ²³INSERM, U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, 75013 Paris, France. ²⁴GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department Child Neurology and Reference Center for Neuromuscular Diseases "Nord/Est/Ile-de-France", FILNEMUS, Armand Trousseau Hospital, GHUEP, AP-HP, Paris 75012, France. ²⁵GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department of Child Neurology and National Reference Center for Neurogenetic Disorders, Armand Trousseau Hospital, GHUEP, AP-HP, INSERM U1141, 75012 Paris, France. ²⁶Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond VA 23298, USA. ²⁷Clinical Genetics Department, University Medical Center Groningen, Groningen 9700RB, The Netherlands. ²⁸Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 08826, Republic of Korea. ²⁹Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul 08826, Republic of Korea. ³⁰Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7HE, UK. ³¹GeneDx, Gaithersburg MD 20877, USA. ³²Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany. ³³Northwell Health, Division of Medical Genetics and Genomics, Great Neck NY 11021, USA. ³⁴Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht 3508AB, The Netherlands. ³⁵University Hospitals Bristol, Department of Clinical Genetics, St Michael's Hospital, Bristol BS2 8EG, UK. ³⁶Department of Clinical Genetics, University Children's Hospital, Paracelsus Medical University, Salzburg A-5020, Austria. ³⁷Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg A-5020, Austria. ³⁸Institute of Human Genetics, Technische Universität München, Munich 81675, Germany. ³⁹Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg 85764, Germany. ⁴⁰Communication Sciences and Disorders, Augustana College, Rock Island IL 61201, USA. ⁴¹Department of Neurology, Mayo Clinic, Rochester MN 55905, USA. ⁴²Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany. ⁴³Waseda University, Tokyo 169-8050, Japan. ⁴⁴Equipe Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon 21070, France. ⁴⁵Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon 21079, France. ⁴⁶Waisman Center, Phonology Project, Madison WI 53705-2280, USA. ⁴⁷Sainte-Justine Hospital, University of Montreal, Montreal QC H3T 1C5, Canada. These authors contributed equally: Lot Snijders Blok, Justine Rousseau, Joanna Twist. These authors jointly supervised this work: Simon E. Fisher, Philippe M. Campeau. A full list of consortium members appears below.

The DDD study

Jeremy F. McRae⁴⁸, Stephen Clayton⁴⁸, Tomas W. Fitzgerald⁴⁸, Joanna Kaplanis⁴⁸, Elena Prigmore⁴⁸, Diana Rajan⁴⁸, Alejandro Sifrim⁴⁸, Stuart Aitken⁴⁹, Nadia Akawi⁴⁸, Mohsan Alvi⁵⁰, Kirsty Ambridge⁴⁸, Daniel M. Barrett⁴⁸, Tanya Bayzatinova⁴⁸, Philip Jones⁴⁸, Wendy D. Jones⁴⁸, Daniel King⁴⁸, Netravathi Krishnappa⁴⁸, Laura E. Mason⁴⁸, Tarjinder Singh⁴⁸, Adrian R. Tivey⁴⁸, Munaza Ahmed^{51,52,53}, Uruj Anjum⁵⁴, Hayley Archer^{55,56}, Ruth Armstrong⁵⁷, Jana Awada⁴⁸, Meena Balasubramanian⁵⁸, Siddharth Banka⁵⁹, Diana Baralle^{51,52,53}, Angela Barnicoat⁶⁰, Paul Batstone⁶¹, David Baty⁶², Chris Bennett⁶³, Jonathan Berg⁶², Birgitta Bernhard⁶⁴, A. Paul Bevan⁴⁸, Maria Bitner-Glindzicz⁶⁰, Edward Blair⁶⁵, Moira Blyth⁶³, David Bohanna⁶⁶, Louise Bourdon⁶⁴, David Bourn⁶⁷, Lisa Bradley⁶⁸, Angela Brady⁶⁴, Simon Brent⁴⁸, Carole Brewer⁶⁹, Kate Brunstrom⁶⁰, David J. Bunyan^{51,52,53}, John Burn⁶⁷, Natalie Canham⁶⁴, Bruce Castle⁶⁹, Kate Chandler⁵⁹, Elena Chatzimichali⁴⁸, Deirdre Cilliers⁶⁵, Angus Clarke^{55,56}, Susan Clasper⁶⁵, Jill Clayton-Smith⁵⁹, Virginia Clowes⁶⁴, Andrea Coates⁶³, Trevor Cole⁶⁶, Irina Colgiu⁴⁸, Amanda Collins^{51,52,53}, Morag N. Collinson^{51,52,53}, Fiona Connell⁷⁰, Nicola Cooper⁶⁶, Helen Cox⁶⁶, Lara Cresswell⁷¹, Gareth Cross⁷²,

Yanick Crow⁵⁹, Mariella D'Alessandro⁶¹, Tabib Dabir⁶⁸, Rosemarie Davidson⁷³, Sally Davies^{55,56}, Dylan de Vries⁴⁸, John Dean⁶¹, Charu Deshpande⁷⁰, Gemma Devlin⁶⁹, Abhijit Dixit⁷², Angus Dobbie⁶³, Alan Donaldson⁷⁴, Dian Donnai⁵⁹, Deirdre Donnelly⁶⁸, Carina Donnelly⁵⁹, Angela Douglas⁷⁵, Sofia Douzou⁵⁹, Alexis Duncan⁷³, Jacqueline Eason⁷², Sian Ellard⁶⁹, Ian Ellis⁷⁵, Frances Elmslie⁵⁴, Karenza Evans^{55,56}, Sarah Everest⁶⁹, Tina Fendick⁷⁰, Richard Fisher⁶⁷, Frances Flinter⁷⁰, Nicola Foulds^{51,52,53}, Andrew Fry^{55,56}, Alan Fryer⁷⁵, Carol Gardiner⁷³, Lorraine Gaunt⁵⁹, Neeti Ghali⁶⁴, Richard Gibbons⁶⁵, Harinder Gill⁷⁶, Judith Goodship⁶⁷, David Goudie⁶², Emma Gray⁴⁸, Andrew Green⁷⁶, Philip Greene⁴⁸, Lynn Greenhalgh⁷⁵, Susan Gribble⁴⁸, Rachel Harrison⁷², Lucy Harrison^{51,52,53}, Victoria Harrison^{51,52,53}, Rose Hawkins⁷⁴, Liu He⁴⁸, Stephen Hellens⁶⁷, Alex Henderson⁶⁷, Sarah Hewitt⁶³, Lucy Hildyard⁴⁸, Emma Hobson⁶³, Simon Holden⁵⁷, Muriel Holder⁶⁴, Susan Holder⁶⁴, Georgina Hollingsworth⁶⁰, Tessa Homfray⁵⁴, Mervyn Humphreys⁶⁸, Jane Hurst⁶⁰, Ben Hutton⁴⁸, Stuart Ingram⁵⁸, Melita Irving⁷⁰, Lily Islam⁶⁶, Andrew Jackson⁴⁹, Joanna Jarvis⁶⁶, Lucy Jenkins⁶⁰, Diana Johnson⁵⁸, Elizabeth Jones⁵⁹, Dragana Josifova⁷⁰, Shelagh Joss⁷³, Beckie Kaemba⁷¹, Sandra Kazembe⁷¹, Rosemary Kelsell⁴⁸, Bronwyn Kerr⁵⁹, Helen Kingston⁵⁹, Usha Kini⁶⁵, Esther Kinning⁷³, Gail Kirby⁶⁶, Claire Kirk⁶⁸, Emma Kivuva⁶⁹, Alison Kraus⁶³, Dhavendra Kumar^{55,56}, V.K.Ajith Kumar⁶⁰, Katherine Lachlan^{51,52,53}, Wayne Lam⁴⁹, Anne Lampe⁴⁹, Caroline Langman⁷⁰, Melissa Lees⁶⁰, Derek Lim⁶⁶, Cheryl Longman⁷³, Gordon Lowther⁷³, Sally A. Lynch⁷⁶, Alex Magee⁶⁸, Eddy Maher⁴⁹, Alison Male⁶⁰, Sahar Mansour⁵⁴, Karen Marks⁵⁴, Katherine Martin⁷², Una Maye⁷⁵, Emma McCann⁷⁷, Vivienne McConnell⁶⁸, Meriel McEntagart⁵⁴, Ruth McGowan⁶¹, Kirsten McKay⁶⁶, Shane McKee⁶⁸, Dominic J. McMullan⁶⁶, Susan McNerlan⁶⁸, Catherine McWilliam⁶¹, Sarju Mehta⁵⁷, Kay Metcalfe⁵⁹, Anna Middleton⁴⁸, Zosia Miedzybrodzka⁶¹, Emma Miles⁵⁹, Shehla Mohammed⁷⁰, Tara Montgomery⁶⁷, David Moore⁴⁹, Sian Morgan^{55,56}, Jenny Morton⁶⁶, Hood Mugalaasi^{55,56}, Victoria Murday⁷³, Helen Murphy⁵⁹, Swati Naik⁶⁶, Andrea Nemeth⁶⁵, Louise Nevitt⁵⁸, Andrew Norman⁶⁶, Rosie O'Shea⁷⁶, Caroline Ogilvie⁷⁰, Kai-Ren Ong⁶⁶, Soo-Mi Park⁵⁷, Michael J. Parker⁵⁸, Chirag Patel⁶⁶, Joan Paterson⁵⁷, Stewart Payne⁶⁴, Daniel Perrett⁴⁸, Julie Phipps⁶⁵, Daniela T. Pilz⁷³, Martin Pollard⁴⁸, Caroline Pottinger⁷⁷, Joanna Poulton⁶⁵, Norman Pratt⁶², Katrina Prescott⁶³, Abigail Pridham⁶⁵, Annie Procter^{55,56}, Hellen Purnell⁶⁵, Oliver Quarrell⁵⁸, Nicola Ragge⁶⁶, Raheleh Rahbari⁴⁸, Josh Randall⁴⁸, Lucy Raymond⁵⁷, Debbie Rice⁶², Leema Robert⁷⁰, Eileen Roberts⁷⁴, Jonathan Roberts⁵⁷, Paul Roberts⁶³, Gillian Roberts⁷⁵, Alison Ross⁶¹, Elisabeth Rosser⁶⁰, Anand Sagar⁵⁴, Shalaka Samant⁶¹, Julian Sampson^{55,56}, Richard Sandford⁵⁷, Ajoy Sarkar⁷², Susann Schweiger⁶², Richard Scott⁶⁰, Ingrid Scurr⁷⁴, Ann Selby⁷², Anneke Seller⁶⁵, Cheryl Sequeira⁶⁴, Nora Shannon⁷², Saba Sharif⁶⁶, Charles Shaw-Smith⁶⁹, Emma Shearing⁵⁸, Debbie Shears⁶⁵, Eamonn Sheridan⁶³, Ingrid Simonic⁵⁷, Roldan Singzon⁶⁴, Zara Skitt⁵⁹, Audrey Smith⁶³, Kath Smith⁵⁸, Sarah Smithson⁷⁴, Linda Sneddon⁶⁷, Miranda Splitt⁶⁷, Miranda Squires⁶³, Fiona Stewart⁶⁸, Helen Stewart⁶⁵, Volker Straub⁶⁷, Mohnish Suri⁷², Vivienne Sutton⁷⁵, Ganesh Jawahar Swaminathan⁴⁸, Elizabeth Sweeney⁷⁵, Kate Tatton-Brown⁵⁴, Cat Taylor⁵, Rohan Taylor⁵⁴, Mark Tein⁶⁶, I. Karen Temple^{51,52,53}, Jenny Thomson⁶³, Marc Tischkowitz⁵⁷, Susan Tomkins⁷⁴, Audrey Torokwa^{51,52,53}, Becky Treacy⁵⁷, Claire Turner⁶⁹, Peter Turnpenny⁶⁹, Carolyn Tysoe⁶⁹, Anthony Vandersteen⁶⁴, Vinod Varghese^{55,56}, Pradeep Vasudevan⁷¹, Parthiban Vijayarangakannan⁴⁸, Julie Vogt⁶⁶, Emma Wakeling⁶⁴, Sarah Wallwark⁵⁷, Jonathon Waters⁶⁰, Astrid Weber⁷⁵, Diana Wellesley^{51,52,53}, Margo Whiteford⁷³, Sara Widaa⁴⁸, Sarah Wilcox⁵⁷, Emily Wilkinson⁴⁸, Denise Williams⁶⁶, Nicola Williams⁷³, Louise Wilson⁶⁰, Geoff Woods⁵⁷, Christopher Wragg⁷⁴, Michael Wright⁶⁷, Laura Yates⁶⁷, Michael Yau⁷⁰, Chris Nellåker^{78,79,80}, Michael Parker⁸¹, Helen V. Firth^{48,57}, Caroline F. Wright⁴⁸, David R. FitzPatrick^{48,49}, Jeffrey C. Barrett⁴⁸ & Matthew E. Hurler⁴⁸

⁴⁸Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK. ⁴⁹MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. ⁵⁰Department of Engineering Science, University of Oxford, Parks Road, Oxford OX1 3PJ, UK. ⁵¹Wessex Clinical Genetics Service, University Hospital Southampton, Princess Anne Hospital, Coxford Road, Southampton SO16 5YA, UK. ⁵²Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire SP2 8BJ, UK. ⁵³Faculty of Medicine, University of Southampton, Building 85, Life Sciences Building, Highfield Campus, Southampton SO17 1BJ, UK. ⁵⁴South West Thames Regional Genetics Centre, St George's Healthcare NHS Trust, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK. ⁵⁵Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK. ⁵⁶Department of Clinical Genetics, Block 12, Glan Clwyd Hospital, Rhyl, Denbighshire LL18 5UJ, UK. ⁵⁷East Anglian Medical Genetics Service, Box 134, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. ⁵⁸Sheffield Regional Genetics Services, Sheffield Children's NHS Trust, Western Bank, Sheffield S10 2TH, UK. ⁵⁹Manchester Centre for Genomic Medicine, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK. ⁶⁰North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street Hospital, Great Ormond Street, London WC1N3JH, UK. ⁶¹North of Scotland Regional Genetics Service, NHS Grampian, Department of Medical Genetics Medical School, Foresterhill, Aberdeen AB25 2ZD, UK. ⁶²East of Scotland Regional Genetics Service, Human Genetics Unit, Pathology Department, NHS Tayside, Ninewells Hospital, Dundee DD1 9SY, UK. ⁶³Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Department of Clinical Genetics, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. ⁶⁴North West Thames Regional Genetics Centre, North West London Hospitals NHS Trust, The Kennedy Galton Centre, Northwick Park and St Mark's NHS Trust Watford Road, Harrow HA1 3UJ, UK. ⁶⁵Oxford Regional Genetics Service, Oxford Radcliffe Hospitals NHS Trust, The Churchill Old Road, Oxford OX3 7LJ, UK. ⁶⁶West Midlands Regional Genetics Service, Birmingham Women's NHS Foundation Trust, Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TG, UK. ⁶⁷Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Institute of Human Genetics, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK. ⁶⁸Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK. ⁶⁹Peninsula Clinical Genetics Service, Royal Devon and Exeter NHS Foundation Trust, Clinical Genetics Department, Royal Devon & Exeter Hospital (Heavitree), Gladstone Road, Exeter EX1 2ED, UK. ⁷⁰South East Thames Regional Genetics Centre, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. ⁷¹Leicestershire Genetics Centre, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary (NHS Trust), Leicester LE1 5WW, UK. ⁷²Nottingham Regional Genetics Service, City Hospital Campus, Nottingham University Hospitals NHS Trust, The Gables, Hucknall Road, Nottingham NG5 1PB, UK. ⁷³West of Scotland Regional Genetics Service, NHS Greater Glasgow and Clyde, Institute of Medical Genetics, Yorkhill Hospital, Glasgow G3 8SJ, UK. ⁷⁴Bristol Genetics Service (Avon, Somerset, Gloucs and West Wilts), University Hospitals Bristol NHS Foundation Trust, St Michael's Hospital, St Michael's Hill, Bristol BS2 8DT, UK. ⁷⁵Merseyside and Cheshire Genetics Service, Liverpool Women's NHS Foundation Trust, Department of Clinical Genetics, Royal Liverpool Children's Hospital Alder Hey, Eaton Road, Liverpool L12 2AP, UK. ⁷⁶National Centre for Medical Genetics, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. ⁷⁷Department of Clinical Genetics, Block 12, Glan Clwyd Hospital, Rhyl, Denbighshire LL18 5UJ Wales, UK. ⁷⁸Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Level 3, Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. ⁷⁹Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK. ⁸⁰Big Data Institute, University of Oxford, Roosevelt drive, Oxford OX3 7LF, UK. ⁸¹The Ethox Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK